Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed ...

The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe ...

Managing maximum tolerated dose (MTD) chemotherapy while minimizing neutropenia relies on precise complete blood count (CBC) monitoring and AI-powered diagnostics.

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might experience loss of balance and coordination ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...